RU2385718C2 - Лечение угрей с использованием производных 5-аминолевулиновой кислоты - Google Patents
Лечение угрей с использованием производных 5-аминолевулиновой кислоты Download PDFInfo
- Publication number
- RU2385718C2 RU2385718C2 RU2007115601/15A RU2007115601A RU2385718C2 RU 2385718 C2 RU2385718 C2 RU 2385718C2 RU 2007115601/15 A RU2007115601/15 A RU 2007115601/15A RU 2007115601 A RU2007115601 A RU 2007115601A RU 2385718 C2 RU2385718 C2 RU 2385718C2
- Authority
- RU
- Russia
- Prior art keywords
- ala
- acne
- photosensitizer
- ester
- ether
- Prior art date
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 114
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 98
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical class NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 title claims abstract description 70
- 238000011282 treatment Methods 0.000 title claims abstract description 44
- -1 benzyl ester Chemical class 0.000 claims abstract description 104
- 229960002749 aminolevulinic acid Drugs 0.000 claims abstract description 45
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 15
- 150000004702 methyl esters Chemical class 0.000 claims abstract description 14
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 241000186429 Propionibacterium Species 0.000 claims abstract description 3
- 239000003504 photosensitizing agent Substances 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 39
- 241000186427 Cutibacterium acnes Species 0.000 claims description 15
- 241000024188 Andala Species 0.000 claims description 14
- 241001464975 Cutibacterium granulosum Species 0.000 claims description 13
- 241001464974 Cutibacterium avidum Species 0.000 claims description 12
- 230000000699 topical effect Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000002186 photoactivation Effects 0.000 claims description 7
- 229940055019 propionibacterium acne Drugs 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 3
- 241001303601 Rosacea Species 0.000 claims description 2
- 229940055009 propionibacterium avidum Drugs 0.000 claims description 2
- 201000004700 rosacea Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 21
- 239000000126 substance Substances 0.000 abstract description 6
- 206010015150 Erythema Diseases 0.000 abstract description 4
- 208000002193 Pain Diseases 0.000 abstract description 4
- 230000002411 adverse Effects 0.000 abstract description 3
- 231100000321 erythema Toxicity 0.000 abstract description 3
- 230000007794 irritation Effects 0.000 abstract description 3
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 208000003251 Pruritus Diseases 0.000 abstract description 2
- 208000005298 acute pain Diseases 0.000 abstract description 2
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 230000002497 edematous effect Effects 0.000 abstract description 2
- 230000009610 hypersensitivity Effects 0.000 abstract description 2
- 230000007803 itching Effects 0.000 abstract description 2
- 230000002035 prolonged effect Effects 0.000 abstract description 2
- 229940127554 medical product Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 38
- 238000002428 photodynamic therapy Methods 0.000 description 35
- 125000000217 alkyl group Chemical group 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 25
- 239000000203 mixture Substances 0.000 description 25
- 150000002148 esters Chemical class 0.000 description 22
- 241000894006 Bacteria Species 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 20
- 238000011534 incubation Methods 0.000 description 20
- 150000004032 porphyrins Chemical class 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 18
- 125000003118 aryl group Chemical group 0.000 description 17
- ILBBNQMSDGAAPF-UHFFFAOYSA-N 1-(6-hydroxy-6-methylcyclohexa-2,4-dien-1-yl)propan-1-one Chemical compound CCC(=O)C1C=CC=CC1(C)O ILBBNQMSDGAAPF-UHFFFAOYSA-N 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 13
- 239000006071 cream Substances 0.000 description 12
- 230000002757 inflammatory effect Effects 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 206010037888 Rash pustular Diseases 0.000 description 11
- 230000035515 penetration Effects 0.000 description 11
- 208000029561 pustule Diseases 0.000 description 11
- 231100000419 toxicity Toxicity 0.000 description 11
- 230000001988 toxicity Effects 0.000 description 11
- 206010033733 Papule Diseases 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 230000003902 lesion Effects 0.000 description 10
- 239000002738 chelating agent Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 208000031513 cyst Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 241001635598 Enicostema Species 0.000 description 7
- 206010027626 Milia Diseases 0.000 description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 210000001732 sebaceous gland Anatomy 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 230000004907 flux Effects 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 231100000086 high toxicity Toxicity 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- YUUAYBAIHCDHHD-UHFFFAOYSA-N methyl 5-aminolevulinate Chemical compound COC(=O)CCC(=O)CN YUUAYBAIHCDHHD-UHFFFAOYSA-N 0.000 description 5
- 230000002165 photosensitisation Effects 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 125000000547 substituted alkyl group Chemical group 0.000 description 5
- RKTMLPDIXLJDMA-UHFFFAOYSA-N 1-fluoro-2-[(2-fluorophenyl)methoxymethyl]benzene Chemical compound FC1=CC=CC=C1COCC1=CC=CC=C1F RKTMLPDIXLJDMA-UHFFFAOYSA-N 0.000 description 4
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 4
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 4
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000019400 benzoyl peroxide Nutrition 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- BPIUIOXAFBGMNB-UHFFFAOYSA-N 1-hexoxyhexane Chemical compound CCCCCCOCCCCCC BPIUIOXAFBGMNB-UHFFFAOYSA-N 0.000 description 3
- LDDKBZYKNBNGSA-UHFFFAOYSA-N 1-nitro-3-[(3-nitrophenyl)methoxymethyl]benzene Chemical compound [O-][N+](=O)C1=CC=CC(COCC=2C=C(C=CC=2)[N+]([O-])=O)=C1 LDDKBZYKNBNGSA-UHFFFAOYSA-N 0.000 description 3
- VJJRVNGOHNKPHB-UHFFFAOYSA-N 1-nitro-4-[(4-nitrophenyl)methoxymethyl]benzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1COCC1=CC=C([N+]([O-])=O)C=C1 VJJRVNGOHNKPHB-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N 3-methoxypyridine Chemical compound COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- LXIQJYAYQYNRCS-UHFFFAOYSA-N 4-(4-phenylbutoxy)butylbenzene Chemical compound C=1C=CC=CC=1CCCCOCCCCC1=CC=CC=C1 LXIQJYAYQYNRCS-UHFFFAOYSA-N 0.000 description 3
- 239000004342 Benzoyl peroxide Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 3
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 3
- 239000007990 PIPES buffer Substances 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- HUVXQFBFIFIDDU-UHFFFAOYSA-N aluminum phthalocyanine Chemical compound [Al+3].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 HUVXQFBFIFIDDU-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000009920 chelation Effects 0.000 description 3
- 150000004035 chlorins Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000295 emission spectrum Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 229960003569 hematoporphyrin Drugs 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229960005280 isotretinoin Drugs 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 229940109328 photofrin Drugs 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OYINILBBZAQBEV-UWJYYQICSA-N (17s,18s)-18-(2-carboxyethyl)-20-(carboxymethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18,22,23-tetrahydroporphyrin-2-carboxylic acid Chemical compound N1C2=C(C)C(C=C)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1C(O)=O)=NC1=C(CC(O)=O)C([C@@H](CCC(O)=O)[C@@H]1C)=NC1=C2 OYINILBBZAQBEV-UWJYYQICSA-N 0.000 description 2
- REXQTRHCVRPOMB-UHFFFAOYSA-N 1-chloro-4-[(4-chlorophenyl)methoxymethyl]benzene Chemical compound C1=CC(Cl)=CC=C1COCC1=CC=C(Cl)C=C1 REXQTRHCVRPOMB-UHFFFAOYSA-N 0.000 description 2
- WZKCRJVJFMWNQT-UHFFFAOYSA-N 1-fluoro-3-[(3-fluorophenyl)methoxymethyl]benzene Chemical compound FC1=CC=CC(COCC=2C=C(F)C=CC=2)=C1 WZKCRJVJFMWNQT-UHFFFAOYSA-N 0.000 description 2
- XBXLZNNMEKOYPT-UHFFFAOYSA-N 1-fluoro-4-[(4-fluorophenyl)methoxymethyl]benzene Chemical compound C1=CC(F)=CC=C1COCC1=CC=C(F)C=C1 XBXLZNNMEKOYPT-UHFFFAOYSA-N 0.000 description 2
- SDTORDSXCYSNTD-UHFFFAOYSA-N 1-methoxy-4-[(4-methoxyphenyl)methoxymethyl]benzene Chemical compound C1=CC(OC)=CC=C1COCC1=CC=C(OC)C=C1 SDTORDSXCYSNTD-UHFFFAOYSA-N 0.000 description 2
- LRKLFZPYIDPEHV-UHFFFAOYSA-N 1-methyl-2-[(2-methylphenyl)methoxymethyl]benzene Chemical compound CC1=CC=CC=C1COCC1=CC=CC=C1C LRKLFZPYIDPEHV-UHFFFAOYSA-N 0.000 description 2
- UJIUKTDUCYLQBN-UHFFFAOYSA-N 1-methyl-4-[(4-methylphenyl)methoxymethyl]benzene Chemical compound C1=CC(C)=CC=C1COCC1=CC=C(C)C=C1 UJIUKTDUCYLQBN-UHFFFAOYSA-N 0.000 description 2
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 2
- OXIQTPVKRUSLOJ-UHFFFAOYSA-N 1-propan-2-yl-4-[(4-propan-2-ylphenyl)methoxymethyl]benzene Chemical compound C1=CC(C(C)C)=CC=C1COCC1=CC=C(C(C)C)C=C1 OXIQTPVKRUSLOJ-UHFFFAOYSA-N 0.000 description 2
- AMOYMEBHYUTMKJ-UHFFFAOYSA-N 2-(2-phenylethoxy)ethylbenzene Chemical compound C=1C=CC=CC=1CCOCCC1=CC=CC=C1 AMOYMEBHYUTMKJ-UHFFFAOYSA-N 0.000 description 2
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 description 2
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 2
- 125000002528 4-isopropyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 2
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 230000008952 bacterial invasion Effects 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- NTUCQKRAQSWLOP-UHFFFAOYSA-N propan-2-yloxymethylbenzene Chemical compound CC(C)OCC1=CC=CC=C1 NTUCQKRAQSWLOP-UHFFFAOYSA-N 0.000 description 2
- 229950003776 protoporphyrin Drugs 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 150000003458 sulfonic acid derivatives Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 1
- JTIUZNMNFPZOKN-UHFFFAOYSA-N 1,2,3,4,5-pentafluoro-6-[(2,3,4,5,6-pentafluorophenyl)methoxymethyl]benzene Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1COCC1=C(F)C(F)=C(F)C(F)=C1F JTIUZNMNFPZOKN-UHFFFAOYSA-N 0.000 description 1
- VDPRSOCKHVPZRS-UHFFFAOYSA-N 1-(2-decylsulfanylethyl)pyrrolidin-2-one Chemical compound CCCCCCCCCCSCCN1CCCC1=O VDPRSOCKHVPZRS-UHFFFAOYSA-N 0.000 description 1
- AYMZQSQRCFSZCR-UHFFFAOYSA-N 1-(3,3-dimethylbutoxy)-3,3-dimethylbutane Chemical compound CC(C)(C)CCOCCC(C)(C)C AYMZQSQRCFSZCR-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- POEDHWVTLBLWDA-UHFFFAOYSA-N 1-butylindole-2,3-dione Chemical compound C1=CC=C2N(CCCC)C(=O)C(=O)C2=C1 POEDHWVTLBLWDA-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- DBUJFULDVAZULB-UHFFFAOYSA-N 1-methoxypentane Chemical compound CCCCCOC DBUJFULDVAZULB-UHFFFAOYSA-N 0.000 description 1
- BCAVDSGTTYREGF-UHFFFAOYSA-N 1-methyl-3-[(3-methylphenyl)methoxymethyl]benzene Chemical compound CC1=CC=CC(COCC=2C=C(C)C=CC=2)=C1 BCAVDSGTTYREGF-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- RNMCCPMYXUKHAZ-UHFFFAOYSA-N 2-[3,3-diamino-1,2,2-tris(carboxymethyl)cyclohexyl]acetic acid Chemical compound NC1(N)CCCC(CC(O)=O)(CC(O)=O)C1(CC(O)=O)CC(O)=O RNMCCPMYXUKHAZ-UHFFFAOYSA-N 0.000 description 1
- RXYBLXNJYZXINS-UHFFFAOYSA-N 2-methoxyethyl 5-amino-4-oxopentanoate Chemical compound COCCOC(=O)CCC(=O)CN RXYBLXNJYZXINS-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- PWRRZALULPEHOC-UHFFFAOYSA-N 2-methyl-1-(2-methylpentoxy)pentane Chemical compound CCCC(C)COCC(C)CCC PWRRZALULPEHOC-UHFFFAOYSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HYDWALOBQJFOMS-UHFFFAOYSA-N 3,6,9,12,15-pentaoxaheptadecane Chemical compound CCOCCOCCOCCOCCOCC HYDWALOBQJFOMS-UHFFFAOYSA-N 0.000 description 1
- VAJVGAQAYOAJQI-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-3,8,13,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C(C=C2C(C)=CC(N2)=CC=2C(=C(CCC(O)=O)C(=C3)N=2)C)=CC(C)=C1C=C1C(C)=C(CCC(O)=O)C3=N1 VAJVGAQAYOAJQI-UHFFFAOYSA-N 0.000 description 1
- DDCZIBJTHVPXFT-UHFFFAOYSA-N 3-hexan-3-yloxyhexane Chemical compound CCCC(CC)OC(CC)CCC DDCZIBJTHVPXFT-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- RYQOILLJDKPETL-UHFFFAOYSA-N 5-aminolevulinic acid hexyl ester Chemical compound CCCCCCOC(=O)CCC(=O)CN RYQOILLJDKPETL-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical class OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- VTQAGEXLVMJCFP-UHFFFAOYSA-N CC(C)C1=CC=C(C=C1)CC(CC(=O)CN)C(=O)O Chemical compound CC(C)C1=CC=C(C=C1)CC(CC(=O)CN)C(=O)O VTQAGEXLVMJCFP-UHFFFAOYSA-N 0.000 description 1
- SYWOSHKZXSCBKF-UHFFFAOYSA-N CC1=CC=C(CC(C(=O)O)CC(=O)CN)C=C1 Chemical compound CC1=CC=C(CC(C(=O)O)CC(=O)CN)C=C1 SYWOSHKZXSCBKF-UHFFFAOYSA-N 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 102000003875 Ferrochelatase Human genes 0.000 description 1
- 108010057394 Ferrochelatase Proteins 0.000 description 1
- KGHNSNSWRMJVND-UHFFFAOYSA-N Hypocrellin Natural products COC1=CC(=O)C2=C3C4C(C(C(=O)C)C(C)(O)Cc5c(OC)c(O)c6C(=O)C=C(OC)C(=C13)c6c45)C(=C2O)OC KGHNSNSWRMJVND-UHFFFAOYSA-N 0.000 description 1
- 206010058015 Infected cyst Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 241001486234 Sciota Species 0.000 description 1
- 239000000589 Siderophore Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 150000004036 bacteriochlorins Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- AFFZCQDLQIEQGB-UHFFFAOYSA-N benzyl 5-amino-4-oxopentanoate Chemical compound NCC(=O)CCC(=O)OCC1=CC=CC=C1 AFFZCQDLQIEQGB-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940002658 differin Drugs 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229940097293 hexyl 5-aminolevulinate Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- UJYSYPVQHFNBML-UHFFFAOYSA-N methyl 5-aminolevulinate hydrochloride Chemical compound [Cl-].COC(=O)CCC(=O)C[NH3+] UJYSYPVQHFNBML-UHFFFAOYSA-N 0.000 description 1
- 229940120732 methyl aminolevulinate hydrochloride Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 125000006502 nitrobenzyl group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229940073067 panoxyl Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical class N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229940002683 retin-a Drugs 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- LYPFDBRUNKHDGX-UHFFFAOYSA-N temoporfin Chemical compound OC1=CC=CC(C=2C3=CC=C(N3)C(C=3C=C(O)C=CC=3)=C3C=CC(=N3)C(C=3C=C(O)C=CC=3)=C3C=CC(N3)=C(C=3C=C(O)C=CC=3)C=3CCC=2N=3)=C1 LYPFDBRUNKHDGX-UHFFFAOYSA-N 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 150000002266 vitamin A derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0616—Skin treatment other than tanning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Semiconductor Lasers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0424833.2 | 2004-11-10 | ||
| GB0424833A GB0424833D0 (en) | 2004-11-10 | 2004-11-10 | Method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007115601A RU2007115601A (ru) | 2008-12-20 |
| RU2385718C2 true RU2385718C2 (ru) | 2010-04-10 |
Family
ID=33523497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007115601/15A RU2385718C2 (ru) | 2004-11-10 | 2005-11-04 | Лечение угрей с использованием производных 5-аминолевулиновой кислоты |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20080188558A1 (https=) |
| EP (1) | EP1814534B1 (https=) |
| JP (1) | JP5134370B2 (https=) |
| CN (1) | CN101056626B (https=) |
| AT (1) | ATE469674T1 (https=) |
| AU (1) | AU2005303565B2 (https=) |
| CA (1) | CA2586195C (https=) |
| DE (1) | DE602005021677D1 (https=) |
| DK (1) | DK1814534T3 (https=) |
| ES (1) | ES2344986T3 (https=) |
| GB (1) | GB0424833D0 (https=) |
| PL (1) | PL1814534T3 (https=) |
| PT (1) | PT1814534E (https=) |
| RU (1) | RU2385718C2 (https=) |
| SI (1) | SI1814534T1 (https=) |
| WO (1) | WO2006051269A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2635563C2 (ru) * | 2012-08-03 | 2017-11-14 | ФотоКьюэр АСА | Соединения |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0525504D0 (en) | 2005-12-14 | 2006-01-25 | Bristol Myers Squibb Co | Antimicrobial composition |
| US20110224598A1 (en) * | 2010-03-12 | 2011-09-15 | Daniel Barolet | Radiant near infrared light emitting diode exposure as skin preparation |
| GB0609809D0 (en) * | 2006-05-17 | 2006-06-28 | Photocure Asa | Product |
| KR100796450B1 (ko) * | 2006-06-29 | 2008-01-22 | 전남대학교산학협력단 | 5-아미노레불린산의 불포화 알킬 에스터 및 약학적으로허용되는 그의 염, 이의 제조방법 및 이의 용도 |
| GB0700580D0 (en) * | 2007-01-11 | 2007-02-21 | Photocure Asa | Use |
| EP2644228A1 (en) | 2007-06-27 | 2013-10-02 | The General Hospital Corporation | Method and apparatus for optical inhibition of photodynamic therapy |
| AU2008337067A1 (en) | 2007-12-14 | 2009-06-25 | Photoderma Sa | Novel compounds useful in therapeutic and cosmetic methods |
| GB0823265D0 (en) * | 2008-12-20 | 2009-01-28 | Convatec Technologies Inc | Antimicrobial Composition |
| GB0823472D0 (en) | 2008-12-23 | 2009-01-28 | Photocure Asa | Product |
| GB0900461D0 (en) | 2009-01-12 | 2009-02-11 | Photocure Asa | Photodynamic therapy device |
| RU2526803C2 (ru) | 2009-06-11 | 2014-08-27 | ФотоКьюэр АСА | Полутвердые композиции и фармацевтические продукты |
| CA2790827A1 (en) | 2010-03-01 | 2011-09-09 | Photocure Asa | Cosmetic compositions |
| EP2585111A1 (en) | 2010-06-23 | 2013-05-01 | Photocure ASA | Hyperosmotic preparations comprising 5 -amino levulinic acid or derivative as photosensitizing agent |
| JP5991970B2 (ja) | 2010-07-09 | 2016-09-14 | フォトキュア エイエスエイ | 光力学的治療または光力学的診断で使用する乾燥組成物および当該乾燥組成物を含む装置 |
| AU2011293132C1 (en) | 2010-08-27 | 2016-04-21 | Sebacia, Inc. | Compositions and methods for targeted thermomodulation |
| US9572880B2 (en) | 2010-08-27 | 2017-02-21 | Sienna Biopharmaceuticals, Inc. | Ultrasound delivery of nanoparticles |
| GB201020236D0 (en) | 2010-11-30 | 2011-01-12 | Convatec Technologies Inc | A composition for detecting biofilms on viable tissues |
| WO2012086802A1 (ja) | 2010-12-24 | 2012-06-28 | アークレイ株式会社 | 癌細胞の検出方法 |
| KR101308652B1 (ko) * | 2011-05-19 | 2013-09-13 | 제너럴바이오(주) | Ｍａｌ을 이용한 여드름 치료 조성물 |
| US20140316534A1 (en) | 2011-10-14 | 2014-10-23 | Photocure Asa | Stent |
| EP2766049A1 (en) | 2011-10-14 | 2014-08-20 | Photocure ASA | Photodynamic diagnosis of abnormalities of the epithelial lining of the oesophagus with the means of a 5-ala ester |
| RU2615870C2 (ru) | 2011-12-19 | 2017-04-11 | ФотоКьюэр АСА | Устройство облучения |
| WO2013092936A2 (en) * | 2011-12-20 | 2013-06-27 | Galderma Research & Development | Use of 5-aminolevulinic acid and esters, in combination with a vitamin d derivative or analog in photochemotherapy, and their uses in treating acne |
| WO2014026077A1 (en) * | 2012-08-10 | 2014-02-13 | Dusa Pharmaceuticals, Inc. | Method for the treatment of acne |
| US20140067024A1 (en) | 2012-08-30 | 2014-03-06 | Photocure Asa | Dual panel photodynamic therapy lamp |
| CA2887687A1 (en) | 2012-10-11 | 2014-04-17 | Nanocomposix, Inc. | Silver nanoplate compositions and methods |
| JP2016507663A (ja) | 2012-12-20 | 2016-03-10 | コンバテック・テクノロジーズ・インコーポレイテッドＣｏｎｖａｔｅｃ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ | 化学修飾セルロース系繊維の加工 |
| KR101623553B1 (ko) * | 2013-07-23 | 2016-05-23 | 동성제약주식회사 | 여드름 치료, 예방 또는 개선에 유효한 클로린 e6 |
| JP6595484B2 (ja) * | 2013-12-20 | 2019-10-23 | ガルデルマ・リサーチ・アンド・デヴェロップメント | 光損傷皮膚のパルス光力学的処置 |
| DK3091919T3 (da) * | 2014-01-10 | 2025-01-02 | Coronado Aesthetics Llc | Behandlingsintervaller til brug af sammensætninger, der indeholder energiabsorberende materialer til dermatologiske anvendelser |
| US9956426B2 (en) | 2015-02-26 | 2018-05-01 | Amol Punjabi | Upconverting nanoparticles |
| US20160287615A1 (en) * | 2015-04-03 | 2016-10-06 | BioPharmX, Inc. | Novel encapsulation of fluorescent, photo-sensitive, or oxygen-sensitive active ingredient for topical application |
| US10603508B2 (en) | 2015-10-15 | 2020-03-31 | Dusa Pharmaceuticals, Inc. | Adjustable illuminators and methods for photodynamic therapy and diagnosis |
| EP3362145B1 (en) | 2015-10-15 | 2021-01-06 | DUSA Pharmaceuticals, Inc. | Adjustable illuminator for photodynamic therapy and diagnosis |
| CN106801037B (zh) * | 2017-01-06 | 2021-01-19 | 中国人民解放军南京军区福州总医院 | 体外痤疮炎症模型的建立方法及其应用 |
| US10632324B2 (en) | 2017-04-27 | 2020-04-28 | 9127-4910 Quebec Inc. | Method for the treatment of skin tissues |
| US20200261580A1 (en) * | 2017-07-17 | 2020-08-20 | Andrea Willey | Photodynamic Therapy Method for Skin Disorders |
| US10357567B1 (en) | 2018-01-12 | 2019-07-23 | Dusa Pharmaceuticals, Inc. | Methods for photodynamic therapy |
| KR102171200B1 (ko) * | 2018-11-20 | 2020-10-28 | 제너럴바이오(주) | 5-아미노레불린산 수화염화물과 그 유도체를 유효성분으로 함유하는 여드름성 피부염 개선 또는 그의 조성물 |
| KR102265592B1 (ko) * | 2020-10-29 | 2021-06-17 | 김진왕 | 5-아미노레불린산 수화염화물을 포함하는 조성물 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996028412A1 (en) * | 1995-03-10 | 1996-09-19 | Photocure As | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
| RU2128506C1 (ru) * | 1993-12-30 | 1999-04-10 | Л'Ореаль | Композиция против угрей с одновременным лечением поверхностных и глубоких слоев кожи и ее применение |
| WO2002013788A1 (en) * | 2000-08-16 | 2002-02-21 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Topical aminolevulinic acid-photodynamic therapy for acne vulgaris |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710066B2 (en) * | 1989-07-28 | 2004-03-23 | Queen's University At Kingston | Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
| US5079262A (en) * | 1989-07-28 | 1992-01-07 | Queen's University At Kingston | Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid |
| US5955490A (en) * | 1989-07-28 | 1999-09-21 | Queen's University At Kingston | Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
| US5422093A (en) * | 1989-07-28 | 1995-06-06 | Queen's University | Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof |
| US5234940A (en) * | 1989-07-28 | 1993-08-10 | Queen's University | Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof |
| US5713845A (en) * | 1991-10-29 | 1998-02-03 | Thermolase Corporation | Laser assisted drug delivery |
| FI951295A7 (fi) | 1992-09-21 | 1995-05-17 | Quadra Logic Tech Inc | Ihon läpi tapahtuva veressä olevien valoherkkien aineiden in vivo-akti vointi |
| GB9700396D0 (en) * | 1997-01-10 | 1997-02-26 | Photocure As | Photochemotherapeutic compositions |
| JPH1112197A (ja) | 1997-06-18 | 1999-01-19 | Cosmo Sogo Kenkyusho:Kk | 悪性腫瘍診断剤及び治療剤 |
| US6183773B1 (en) * | 1999-01-04 | 2001-02-06 | The General Hospital Corporation | Targeting of sebaceous follicles as a treatment of sebaceous gland disorders |
| DE10003620A1 (de) | 2000-01-28 | 2001-08-02 | Asat Ag Applied Science & Tech | 5-Aminolävulinsäure-Formulierung in nichtwässrigen Lösungsmitteln |
| GB0018528D0 (en) * | 2000-07-27 | 2000-09-13 | Photocure Asa | Compounds |
| GB0118251D0 (en) | 2001-07-26 | 2001-09-19 | Photocure Asa | Method |
| US20050090481A1 (en) * | 2001-11-09 | 2005-04-28 | Qlt Inc | Compositions comprising a photosensitizer and a skin-penetration enhancer and their use in photodynamic treatment |
| US20040048842A1 (en) * | 2002-09-10 | 2004-03-11 | Mcmillan Kathleen | Method of treating skin disorders |
| US20050209331A1 (en) * | 2004-03-22 | 2005-09-22 | Syneron Medical Ltd. | Method of treatment of skin |
| US20050209330A1 (en) * | 2004-03-22 | 2005-09-22 | Syneron Medical Ltd. | Method of treatment of skin |
| GB0406917D0 (en) | 2004-03-26 | 2004-04-28 | Photocure Asa | Compounds |
-
2004
- 2004-11-10 GB GB0424833A patent/GB0424833D0/en not_active Ceased
-
2005
- 2005-11-04 AT AT05800149T patent/ATE469674T1/de active
- 2005-11-04 PL PL05800149T patent/PL1814534T3/pl unknown
- 2005-11-04 DK DK05800149.6T patent/DK1814534T3/da active
- 2005-11-04 ES ES05800149T patent/ES2344986T3/es not_active Expired - Lifetime
- 2005-11-04 CN CN2005800384462A patent/CN101056626B/zh not_active Expired - Fee Related
- 2005-11-04 JP JP2007540703A patent/JP5134370B2/ja not_active Expired - Fee Related
- 2005-11-04 CA CA2586195A patent/CA2586195C/en not_active Expired - Fee Related
- 2005-11-04 PT PT05800149T patent/PT1814534E/pt unknown
- 2005-11-04 AU AU2005303565A patent/AU2005303565B2/en not_active Ceased
- 2005-11-04 RU RU2007115601/15A patent/RU2385718C2/ru not_active IP Right Cessation
- 2005-11-04 EP EP05800149A patent/EP1814534B1/en not_active Expired - Lifetime
- 2005-11-04 US US11/667,504 patent/US20080188558A1/en not_active Abandoned
- 2005-11-04 DE DE602005021677T patent/DE602005021677D1/de not_active Expired - Lifetime
- 2005-11-04 WO PCT/GB2005/004253 patent/WO2006051269A1/en not_active Ceased
- 2005-11-04 SI SI200531079T patent/SI1814534T1/sl unknown
-
2012
- 2012-11-09 US US13/673,704 patent/US8546447B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2128506C1 (ru) * | 1993-12-30 | 1999-04-10 | Л'Ореаль | Композиция против угрей с одновременным лечением поверхностных и глубоких слоев кожи и ее применение |
| WO1996028412A1 (en) * | 1995-03-10 | 1996-09-19 | Photocure As | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
| WO2002013788A1 (en) * | 2000-08-16 | 2002-02-21 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Topical aminolevulinic acid-photodynamic therapy for acne vulgaris |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2635563C2 (ru) * | 2012-08-03 | 2017-11-14 | ФотоКьюэр АСА | Соединения |
Also Published As
| Publication number | Publication date |
|---|---|
| PT1814534E (pt) | 2010-06-15 |
| CN101056626A (zh) | 2007-10-17 |
| US8546447B2 (en) | 2013-10-01 |
| US20080188558A1 (en) | 2008-08-07 |
| DK1814534T3 (da) | 2010-09-20 |
| RU2007115601A (ru) | 2008-12-20 |
| CN101056626B (zh) | 2011-12-14 |
| SI1814534T1 (sl) | 2010-09-30 |
| CA2586195A1 (en) | 2006-05-18 |
| AU2005303565A1 (en) | 2006-05-18 |
| DE602005021677D1 (de) | 2010-07-15 |
| JP5134370B2 (ja) | 2013-01-30 |
| JP2008519812A (ja) | 2008-06-12 |
| US20130066256A1 (en) | 2013-03-14 |
| EP1814534B1 (en) | 2010-06-02 |
| EP1814534A1 (en) | 2007-08-08 |
| PL1814534T3 (pl) | 2010-11-30 |
| WO2006051269A1 (en) | 2006-05-18 |
| GB0424833D0 (en) | 2004-12-15 |
| ATE469674T1 (de) | 2010-06-15 |
| AU2005303565B2 (en) | 2011-04-14 |
| ES2344986T3 (es) | 2010-09-13 |
| CA2586195C (en) | 2013-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2385718C2 (ru) | Лечение угрей с использованием производных 5-аминолевулиновой кислоты | |
| US8759396B2 (en) | Use of aminolevulinic acid and derivatives thereof | |
| Sakamoto et al. | Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice: part II. Understanding parameters for acne treatment with photodynamic therapy | |
| EP3082788B1 (en) | Pulse photodynamic treatment of acne | |
| Monfrecola et al. | A critical reappraisal of off-label use of photodynamic therapy for the treatment of non-neoplastic skin conditions | |
| Piergiacomo et al. | A critical reappraisal of off-label indications for topical photodynamic therapy with aminolevulinic acid and methylaminolevulinate | |
| WO2013092936A2 (en) | Use of 5-aminolevulinic acid and esters, in combination with a vitamin d derivative or analog in photochemotherapy, and their uses in treating acne | |
| Curnow et al. | Enhancing protoporphyrin IX-induced photodynamic therapy with a topical iron chelating agent in a normal skin model | |
| Mikolajewska | Asta Juzeniene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20181105 |